Edition:
United States

Amarin Corporation PLC (AMRN.O)

AMRN.O on Consolidated Issue listed on NASDAQ Global Market

3.22USD
9 Dec 2016
Change (% chg)

$-0.04 (-1.23%)
Prev Close
$3.26
Open
$3.26
Day's High
$3.37
Day's Low
$3.22
Volume
1,389,743
Avg. Vol
3,395,561
52-wk High
$3.65
52-wk Low
$1.24

AMRN.O

Chart for AMRN.O

About

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company's lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an... (more)

Overall

Beta: 0.90
Market Cap(Mil.): $880.05
Shares Outstanding(Mil.): 269.95
Dividend: --
Yield (%): --

Financials

  AMRN.O Industry Sector
P/E (TTM): -- 40.79 30.35
EPS (TTM): -0.43 -- --
ROI: -65.71 -0.56 15.27
ROE: -- -1.20 16.60

BRIEF-Amarin Q3 adjusted non-gaap loss per share $0.08

* Maintaining guidance on 2016 net product revenue at $112-$125 million

Nov 03 2016

CORRECTED-BRIEF-Amarin REDUCE-IT cardiovascular outcomes study to continue without changes

* Reduce-It cardiovascular outcomes study of Vascepa to continue as planned at recommendation of independent data monitoring committee

Sep 12 2016

BRIEF-Amarin randomizes final patient into reduce-it cardiovascular outcomes study of Vascepa

* Amarin randomizes final patient into reduce-it cardiovascular outcomes study of Vascepa

Aug 31 2016

BRIEF-Amarin Corporation announces mandatory exchange of some senior notes

* Amarin announces mandatory exchange of exchangeable senior notes issued in may 2014 and november 2015

Aug 26 2016

BRIEF-Amarin announces proposed public offering of American depositary shares

* Amarin announces proposed public offering of American depositary shares Source text for Eikon: Further company coverage:

Aug 10 2016

BRIEF-Amarin Q2 loss per share $0.07

* Amarin reports second quarter 2016 financial results and provides update on operations

Aug 04 2016

BRIEF-Amarin says FDA to amend SPA agreement for cardiovascular outcomes study

* Amarin and FDA reaffirm concurrence on REDUCE-IT through special protocol assessment agreement amendment

Aug 04 2016

BRIEF-Amarin appoints Michael Kalb chief financial officer

* Kalb joins Amarin from Taro Pharmaceutical Industries Ltd Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 30 2016

Competitors

Earnings vs. Estimates